The Potential for microRNA Therapeutics and Clinical Research
By J. Hanna, G. Hossain, J. Kocerha. Frontiers in Genetics, 2019
625 citations recorded by the source corpus.
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of nonprotein-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/777876f47c294fb3356ff9f8afa6d3357c675aca
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Marinka Zitnik
- Kexin Huang
- Jure Leskovec
- Cao Xiao
- Jimeng Sun
- Tianfan Fu
- Yusuf H. Roohani
- Connor W. Coley
Citations in the corpus
- Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development (2021, background): “They can also help identify miRNA hits for miRNA therapeutics candidates (Hanna et al. 2019).”